On Wednesday, Goldman Sachs reiterated its Sell rating on shares of Harmony Biosciences Holdings Inc. (NASDAQ:HRMY), with a steady price target of $28.00. The decision follows Harmony Biosciences' recent Investor Day, held on October 1, which showcased the company's developments in its three core neurology franchises: sleep/wake disorders, neurobehavioral conditions, and epilepsy.
The sleep/wake segment's discussion revolved around the company's drug Wakix, new formulations of pitolisant, and the recently acquired orexin 2 receptor agonist BP1.15205. Despite preclinical data suggesting the OX2R program's best-in-class potency, Goldman Sachs notes that further studies are needed to confirm its potential, as there are other factors like selectivity and half-life that could influence the program's clinical benefits.
In the neurobehavioral domain, Harmony Biosciences presented its synthetic CBD product ZYN002, which is being developed for fragile X syndrome (FXS) and 22q deletion syndrome. The company expressed confidence in the product ahead of Phase 3 data expected in 2025.
For the epilepsy franchise, Harmony Biosciences is focusing on EPX-100 (clemizole hydrochloride) for treating Dravet and Lennox-Gastaut syndrome (DS/LGS). The firm underscored the preclinical evidence of efficacy and the safety profile of EPX-100, with clinical study results anticipated in 2026.
As Harmony Biosciences continues to advance its clinical programs, Goldman Sachs remains cautious, maintaining its Sell rating and $28.00 price target for the company's stock. The financial institution awaits further clinical validation of the company's pipeline before considering any changes to its assessment.
In other recent news, Harmony Biosciences has made substantial strides in its high-dose pitolisant program, which focuses on unmet medical needs in the narcolepsy community. This progress comes alongside a robust Q2 financial report, with net sales for its product WAKIX climbing by 29% to $172.8 million and a solid non-GAAP adjusted net income of $60.6 million. The company maintains a steady financial position, boasting $434.1 million in cash, cash equivalents, and investments. Harmony Biosciences is on track to meet its 2024 net revenue guidance of $700 million to $720 million.
In terms of analyst ratings, Mizuho, Needham, and UBS have all maintained positive positions on Harmony Biosciences, citing the company's strong performance and promising pipeline. The company's FDA approval for WAKIX for pediatric narcolepsy and a planned sNDA for idiopathic hypersomnia later this year are also among the recent developments.
Harmony Biosciences has also provided updates on its pipeline, including promising data on its orexin-2 receptor agonist program and Fragile X syndrome program. The company's CEO, Jeffrey M. Dayno, M.D., has highlighted the potential to generate over $3 billion in annual revenue.
InvestingPro Insights
While Goldman Sachs maintains a cautious stance on Harmony Biosciences Holdings Inc. (NASDAQ:HRMY), recent InvestingPro data reveals some positive aspects of the company's financial performance. HRMY's revenue growth stands at an impressive 31.52% over the last twelve months as of Q2 2024, with a robust gross profit margin of 79.41%. This strong top-line growth and profitability align with the company's focus on advancing its neurology franchises.
InvestingPro Tips highlight that management has been aggressively buying back shares, which could signal confidence in the company's future prospects. Additionally, HRMY's valuation implies a strong free cash flow yield, potentially indicating that the stock might be undervalued relative to its cash-generating abilities.
It's worth noting that HRMY is trading near its 52-week high, with a strong return of 30.8% over the last three months. This recent performance suggests that some investors may be more optimistic about the company's pipeline and growth potential than Goldman Sachs' current rating implies.
For investors seeking a more comprehensive analysis, InvestingPro offers 7 additional tips for HRMY, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.